Molecular Partners Presents Results from a Phase 2a Trial :

First presentation of data from patients treated with ensovibep demonstrate the candidate to be safe and well-tolerated All patients exhibited reductions...

Related Keywords

Netherlands , Zurich , Züsz , Switzerland , Patrick Amstutz , Lutz Hegemann , Marianne Soergel , Twitter , Nasdaq , Novartis , Department Of Infectious Diseases , Centre For Human Drug Research , Global Health For Novartis , Leiden University Medical Center , European Scientific Working Group On Influenza , Group Head Of Corporate Affairs , European Scientific Working Group , Human Drug Research , Group Head , Corporate Affairs , Global Health , Molecular Partner , Molecular Partners , Infectious Diseases , Nasdaq Moln ,